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Rest tremor is one of the cardinal signs of Parkinson’s disease. Kinetic and postural tremors may 
also occur. The coexistence of these three types of tremor at disease onset and their subsequent 
progression could have important clinical and therapeutic implications but remain to be fully 
elucidated. We aimed to: (i) Evaluate prevalence and progression of these three types of tremor in 
early stages of the disease; (ii) Investigate longitudinally the relationship between dopaminergic and 
serotonergic terminal dysfunction, rest tremor severity and its response to dopaminergic therapy.  
The Parkinson’s Progressive Markers Initiative database provided the baseline and two-year follow-
up clinical ratings and 123Ioflupane-Fluoropropyl-Carbomethoxy-3-beta-4-Iodophenyltropane single 
photon emission computed tomography images for this study. 123Ioflupane-Fluoropropyl-
Carbomethoxy-3-beta-4-Iodophenyltropane measured putamen dopamine transporter and median 
raphe serotonin transporter availability. A Raphe/Putamen uptake ratio was calculated for each 
patient as an index of relative involvement of these structures.  
Clinical analysis of tremor was conducted on three hundred and seventy-eight patients. 87.8% 
presented with tremor at baseline. Rest tremor occurred in 69.6% of patients at baseline and 67.9% 
at follow up. Postural and kinetic tremors occurred in about 50% of patients at both baseline and 
follow up. Over 20% of patients presenting with tremor did not exhibit a rest component at 
baseline. The number of patients with isolated rest tremor was halved at follow-up. 
In tremor predominant patients, rest tremor severity was inversely correlated with raphe serotonin 
transporter availability both a baseline and follow-up (baseline: constancy P <0.05, tremor index P 
<0.05; follow-up: amplitude P <0.05, constancy P <0.05, tremor index P <0.05). In the entire 
cohort, more severe tremor scores correlated with lower Raphe/Putamen uptake ratio values, 
indicative of more severe raphe dysfunction (baseline: constancy P <0.01, tremor index P <0.05; 
follow-up: amplitude P <0.01, constancy P <0.001, tremor index P <0.001). The percentage of 
improvement in rest tremor amplitude after acute dopaminergic therapy was smaller in patients with 
lower Raphe/Putamen uptake ratio values (P <0.01).  
Rest tremor is the most represented type of tremor in early Parkinson’s disease. However, postural 
and kinetic tremor can affect approximately half of these patients and can occur in absence of 
resting tremor. As disease progresses, both raphe serotonergic dysfunction and putamen dopamine 
depletion could contribute to the occurrence of rest tremor. The former is linked to more severe 
tremor scores and poorer response to dopaminergic therapy. Non-dopaminergic treatments might be 




Tremor is a rhythmical, involuntary, oscillatory movement of a body part and is clinically classified 
as rest, postural or kinetic tremor according to the state of activation of the limb in which it occurs  
(Deuschl et al., 1998). In Parkinson’s disease, rest tremor is a cardinal feature, which supports the 
diagnosis of the disease. Postural (Jankovic, 2008) and kinetic tremors (Louis and Frucht, 2007) are 
also common manifestations. However, only a few studies have prospectively evaluated the 
progression of tremor over the course of the disease (Louis et al., 1999; Vu et al., 2012) and the 
concomitant prevalence of the three types of tremor in the early stages of the disease has not been 
fully documented.  
The pathophysiology of rest tremor in Parkinson's disease remains poorly understood. Rest tremors 
are often less responsive to dopamine replacement therapy than rigidity and bradykinesia (Fishman, 
2008), suggesting that dopamine deficiency alone does not determine tremor severity, and its 
response to dopaminergic treatments is influenced by other factors.  This clinical observation is 
supported by a number of in vivo PET and SPECT studies. In these studies, tremor severity did not 
correlate with levels of nigrostriatal dysfunction (Benamer et al., 2000; Pirker 2003; Rossi et al., 
2010) and, generally, tremor predominant patients have been reported to have relatively spared 
striatal dopaminergic function (Spiegel et al., 2007; Rossi et al., 2010; Helmich et al., 2011; 
Qamhawi et al., 2015). Conversely, there is growing evidence that rest tremor could be related to 
degeneration of non-dopaminergic systems. Raphe nuclei serotonergic neuronal dysfunction has 
been associated with severity of rest tremor. (Doder et al., 2003; Qamhawi et al., 2015), and 
involvement of the noradrenergic locus coeruleus has also been proposed (Isaias et al., 2011). 
However, nigro-striatal degeneration is still necessary for a Parkinsonian tremor to occur (Deuschl 
et al., 2000) and in clinical practice a significant number of tremors respond to dopamine 
replacement therapy. In one series, dopaminergic depletion in the globus pallidus, rather than in the 
putamen, was found to be  associated with tremor severity (Helmich et al., 2011). 
In this study, we evaluated the prevalence and clinical progression of tremor in the early stages of 
Parkinson's disease. We also examined with 123I-FP-CIT SPECT the relationship between 
dopaminergic and serotonergic terminal dysfunction and rest tremor severity both at baseline and 
after a two- years follow up, and how serotonergic relative to dopaminergic loss influenced the 
response of rest tremor to dopaminergic therapy. In our previous paper, a cross-sectional baseline 
analysis of the PPMI cohort data did not show any correlation between serotonergic or 
dopaminergic dysfunction and severity of postural-kinetic tremor components (Qamhawi et al., 
2015; see also Supplementary Table 4); thus, we did not further investigate the association of 
these two types of tremor and 123I-FP-CIT findings at the two-year follow up. 
In more detail, tThis study includesd four main analyses: 1. Estimating the prevalence of rest, 
postural and kinetic tremors in a large cohort of early Parkinson's disease patients. 2. Evaluating the 
clinical progression of these tremor components from baseline to the two-year follow up. 3. 
Investigating how relative levels of serotonin and dopamine dysfunction measured with 123I-FP-CIT 
SPECT influence rest tremor severity and whether this relationship changes with disease 
progression. 4.  Determining the association between serotonin and dopamine dysfunctions and the 
response of rest tremor to dopaminergic therapy.  
 
Methods 
Study design and participantsThis study included four main analyses: 1. Estimating the 
prevalence of rest, postural and kinetic tremors in a large cohort of early Parkinson's disease 
patients. 2. Evaluating the clinical progression of these tremor components from baseline to the 
two-year follow up. 3. Investigating how relative levels of serotonin and dopamine dysfunction 
measured with 123I-FP-CIT SPECT influence rest tremor severity and whether this relationship 
changes with disease progression. 4.  Determining the association between serotonin and dopamine 
dysfunctions and the response of rest tremor to dopaminergic therapy.  
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All the clinical data and 123I-FP-CIT SPECT images used in this study were downloaded from the 
Parkinson’s Progressive Markers Initiative (PPMI) database. The PPMI is an ongoing longitudinal, 
international, multicentre, observational clinical study of early Parkinson's disease patients aimed at 
identifying disease biomarkers (Marek et al., 2011). The study includes ascertains patients with a 
clinical disease duration of less than two years who periodically undergo clinical motor evaluation 
and imaging with 123I-FP-CIT SPECT. The diagnosis of Parkinson’s disease had to be supported by 
an in vivo evidence of nigrostriatal dopaminergic dysfunction; all patients with tremor and normal 
scans were followed up as a separate group (Scans Without Evidence of Dopaminergic Deficit). 
The full list of inclusion and exclusion criteria can be found in the PPMI study protocol, available 
online at http://www.ppmi-info.org/study-design/research-documents-and-sops/. 
Our analysis was focused on the period from baseline to the two-year follow up, as not enough 
patients had completed longer follow ups. We therefore downloaded clinical motor assessments and 
123I-FP-CIT SPECT images at both baseline and two-year follow up from the PPMI database in 
August 2015. For patients who did not have a two-year assessment the previous or successive one 
was used. 
Baseline clinical assessments were available for 423 patients. Three hundred and ninety-eight of 
these patients had both baseline and two-year follow up assessments available. Eleven patients at 
baseline and nine patients at follow up had a total rest tremor amplitude rated > 0 with a constancy 
rated 0, or vice versa: we assumed that there was an error in data collection and, therefore, these 
patients were excluded. Thus, 378 patients were eligible for the clinical analysis of tremor. 
Two hundred and twenty four patients had both 123I-FP-CIT SPECT and clinical data available at 
the two-year follow up allowing correlational analyses between regional tracer binding and tremor 
component scores. However, the scans of 23 patients did not include the caudal raphe and 28 
patients were taking serotonergic agents at the time of SPECT (26 SSRIs, 2 SNRIs).  These patients 
were excluded leaving a total of 173 patients to be included in the correlational analysis.  
According to the PPMI study protocol, after starting treatment, patients were asked to attend clinic 
visits after overnight withdrawal of their anti-parkinsonian medications. MDS-UPDRS was 
performed in the OFF state and then repeated one hour after receiving medication. Ninety-eight 
patients had both ON and OFF medication assessments in the same follow-up visit (either the two-
year visit or the previous or the successive one) potentially allowing the correlational analyses 
between regional 123I-FP-CIT binding and the tremor response to dopaminergic therapy. However, 
only 38 had a total rest tremor amplitude > 0 and were treated with either levodopa or a dopamine 
agonist alone (as indicated in the UPDRS III sheet) and were included in this correlational analysis. 
 
Clinical evaluation 
Clinical features were rated with the Movement Disorder Society’s Unified Parkinson’s Disease 
Rating Scale (MDS-UPDRS) at baseline and follow up.   
For each patient we recorded: rigidity (highest and total score of item 3.3), body bradykinesia (item 
3.14), bradykinesia scores (items 3.4, 3.5, 3.6, 3.7, 3.8), postural tremor of the hands (item 3.15), 
kinetic tremor of the hands (item 3.16), rest tremor amplitude (item 3.17), rest tremor constancy 
(item 3.18). Then, we calculated: 
 The total score for postural tremor (right and left hands; score range: 0-8) 
 The total score for kinetic tremor (right and left hands; score range: 0-8) 
 The total score for rest tremor amplitude (right and left hands, right and left legs, lip/jaw; 
score range 0-20) 
 The highest score for rest tremor amplitude (score range: 0-4) 
 The index of rest tremor, by multiplying rest tremor amplitude total score and rest tremor 
constancy (score range: 0-80). 
In the comparison of tremor scores between patients with unilateral and bilateral rest tremor, 
the index of rest tremor was calculated using the rest tremor amplitude score of the most 
affected limb (highest score in item 3.17). 
 The percentage improvement in rest tremor amplitude and index of rest tremor scores 
following treatment, calculated as:  
(
𝑡𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑡 𝑡𝑟𝑒𝑚𝑜𝑟 𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒 𝑖𝑛 𝑂𝐹𝐹 − 𝑡𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑡 𝑡𝑟𝑒𝑚𝑜𝑟 𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒 𝑖𝑛 𝑂𝑁
𝑡𝑜𝑡𝑎𝑙 𝑟𝑒𝑠𝑡 𝑡𝑟𝑒𝑚𝑜𝑟 𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒 𝑖𝑛 𝑂𝐹𝐹
) × 100 
 This index was used in order to assess the effect of dopamine replacement therapy. 
 The total bradykinesia score (sum of items 3.4, 3.5, 3.6, 3.7, 3.8; score range: 0-40) 
Patients with an index of rest tremor  2, a rigidity score  1 and a bradykinesia score  1were 
classified as “tremulous” or “isolated rest tremor” patients; patients without rest tremor were 
classified as “without tremor”; patients who did not fall under these conditions were classified as 
“mixed”. We also used Stebbins’ classification (Stebbins et al., 2013) in order to phenotypically 
identify patients as “Tremor Dominant (TD)”, “Postural Instability / Gait Difficulty (PIGD)” or 
“Indeterminate”. 
 
123I-FP-CIT SPECT protocol and Region of Interest analysis 
A detailed description of the 123I-FP-CIT SPECT protocol and the ROI analysis is available in a 
previous article from our group (Qamhawi et al., 2015). We repeated a similar imaging analysis 
with the 123I-FP-CIT SPECT scans available at the two-year follow up. 
Briefly, 123I-FP-CIT SPECT was used to assess dopaminergic and serotonergic transporter 
availability in the putamen and raphe nuclei, respectively. A region of interest analysis was 
performed using Analyze 11.0 software (Mayo clinic, MN, USA) and regional 123I-FP-CIT specific 
binding ratios were measured. Regions of interest were manually drawn on a single subject MRI 
template in Montreal Neurological Institute space available in Statistical Parametric Mapping using 
Analyze 11.0 software (Mayo clinic, MN, USA). Regions of interest sampling the right and left 
putamen were drawn according to their anatomical borders (average regions of interest volumes 530 
mm3 and 478 mm3, respectively). A region of interest sampling the rostral raphe was drawn in the 
midbrain and rostral pons (average volume 591 mm3) and a region of interest for caudal raphe was 
drawn in the lower pons and medulla (average volume 264 mm3), according to the anatomical 
description of Hornung (2003). A region of interest of the left and right occipital cortices was used 
as reference region. 
The MRI template incorporating these regions of interest was loaded onto the SPECT scan of each 
patient using Analyze 11.0. Regions of interest were then inspected for correct alignment along x, y 
and z axes and manually adjusted to account for individual variation, without changing their size 
and shape. Misaligned scans were excluded as stated above. Regions of interest sampling the 
putamen, the rostral and caudal raphe nuclei, and the occipital cortex were drawn on an MRI 
template and transferred onto the SPECT images of each patient; these were then inspected for 
correct alignment along x, y and z axes, and manually adjusted to account for individual variation. 
For each region of interest 123I-FP-CIT specific binding ratio (SBR) was calculated as follows: 
𝑆𝐵𝑅 =
(
𝑚𝑒𝑎𝑛 𝑟𝑒𝑔𝑖𝑜𝑛 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 𝑐𝑜𝑢𝑛𝑡𝑠







This is also defined as the non-displaceable binding potential for tracers at equilibrium (Innis et al., 
2007). 
The average of right and left Putamen was taken as the total Putamen SBR; we will refer to this as 
“Putamen SBR”. The total raphe nuclei SBR was calculated by summing rostral and caudal raphe 
nuclei SBR; this will be referred to as “Raphe SBR”. 
As specific binding ratios for these two total regions of interest were not normally distributed, they 
were normalised logarithmically: ln (SBR + constant). 
 
Raphe / Putamen Ratio 
For each patient the specific 123I-FP-CIT binding ratios were used to calculate the Raphe / Putamen 


















This “Raphe / Putamen” ratio represents raphe serotonin transporter availability normalised to 
putamen dopamine transporter availability. Thus, it expresses the involvement of Raphe and 
Putamen relatively to each other in the single patient: low ratios indicate a predominant dysfunction 
of the Raphe with respect to the Putamen, while higher ratios imply a more profound degeneration 
of the Putamen relatively to the Raphe. The relationship between Raphe and Putamen binding 
values and Raphe / Putamen ratios at follow up is described in The relationship between the Raphe / 
Putamen ratio and Raphe and Putamen specific binding ratios is represented in Supplementary 
Figure 1.  
This ratio allowed us to study the simultaneous contribution of the serotonergic and dopaminergic 
systems to the occurrence of rest tremor scores and their response to dopaminergic therapy.  
The Raphe / Putamen ratio of each patient was calculated at both baseline for a cohort of 345 
patients (thanks to the specific binding ratios made available from a previous study from our group, 
Qamhawi et al., 2015), and at a two-year follow up in the cohort of 173 patients. 
 
Statistical analysis 
In the clinical analyses of tremor, rigidity and bradykinesia, the comparisons of features between 
different groups of patients were assessed with Student’s t-test with a Welch correction in order to 
address for the different groups sizes, the inequality of variances and mild skewness (Zimmerman  
2004; Fagerland & Sandvik 2009; Fagerland et al., 2011).  
For the correlational analyses between tremor scores and Raphe binding values and Raphe / 
Putamen ratios, we used the non-parametric Spearman’s test due to the non-normal distribution of 
tremor scores. 
The association between the percentage improvements in rest tremor amplitude and the Raphe / 
Putamen binding ratios was explored with a linear regression analysis: in this case the assumptions 
of linearity, independence of the errors, homoscedasticity and normality of errors distribution were 
fulfilled.  
The relationship between the follow-up Raphe and Putamen FP-CIT binding values and Raphe / 
Putamen ratios was investigated through a linear regression analysis. 
 
Results  
Clinical evaluation of tremor characteristics  
A total of 378 patients were eligible for the clinical evaluation of tremor characteristics. All patients 
were evaluated in the off-state withdrawn from medication. The clinical and demographic 
characteristics of these patients at the two-year follow up are summarized in Table 1. 
Baseline.  
At baseline 12.2% of patients (n=46) had no tremor, while 87.8% (n=332) presented at least one 
feature of tremor.  
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Rest tremor was present in 69.6% of patients (n=263 of 378). Of these, 88.2% (n=232) had 
unilateral rest tremor while 10.3% (n=27) had bilateral rest tremor; four patients (1.5%) only had lip 
/ jaw tremor (Table 21). Compared to patients with unilateral tremor, patients with bilateral tremor 
had a significantly higher amplitude (1.93 ± 0.68 vs 1.64 ± 0.62, P-value < 0.05), higher constancy 
(2.70 ± 0.91 vs 1.89 ± 0.99, P-value < 0.001), and index (product of amplitude and constancy) of 
rest tremor (5.44 ± 2.76 vs 3.43 ± 2.62 P-value < 0.01) in the most tremulous limb. The 
distributions of tremor scores across unilateral and bilateral tremor groups at baseline are reported 
in Table 32.  
Of the 263 patients showing rest tremor at baseline, 68.4% (n=180) presented with tremor in the 
upper limbs, 6.1% (n=16) in the lower limbs, and 1.5% (n=4) with lip / jaw tremor; 24% (n=63) 
presented with a combination of all three regions affected (Supplementary Figure 2).  
Postural tremor was present in 52.1% of patients (197 of 378); 148 patients had unilateral postural 
tremor while 49 had bilateral postural tremor; in these 197 patients the mean ( SD) total postural 
tremor score was 1.42  0.70.  
Kinetic tremor was evident in 51.6% of patients (n=195 of 378); 118 patients presented with a 
unilateral kinetic tremor and 77 with bilateral kinetic tremor; the mean ( SD) total kinetic tremor 
score in these patients was 1.56  0.70. Results are summarised in Table 21. 
Across the 332 patients with tremor, 24.1% (n=80) had rest tremor alone, 6.0% (n=20) had kinetic 
tremor alone, and 4.5% (n=15) had postural tremor alone. 12.7% (n=42) had rest and postural 
tremor; 10.6% (n=35) had rest and kinetic tremor; and 10.2% (n=34) had postural and kinetic 
tremor. 31.9% of patients (n= 106) had all three components of tremor (Figure 1).  
Compared to patients with postural and/or kinetic tremors, patients presenting only with rest tremor 
showed significantly lower rigidity (3.24  2.094 vs 4.26  2.565, P-value < 0.01) and bradykinesia 
(7.28  4.829 vs 9.04  4.480, P-value < 0.05) (Supplementary Table 1). 
Phenotypically, 43 patients presented isolated rest tremor (rigidity score  1, bradykinesia score  1, 
index tremor  2), 115 had no rest tremor (index tremor = 0) and 220 patients had a mixed 
phenotype. Compared to patients with a mixed phenotype, patients with isolated rest tremor had 
significantly higher rest tremor amplitude total score (2.77 ± 1.4 vs 1.97 ± 1.13, P-value < 0.01), 
rest tremor constancy (2.58 ± 0.91 vs 1.83 ± 0.98, P-value < 0.001) and index of rest tremor (7.42 ± 
5.45 vs 4.18 ± 4.11, P-value < 0.001).  
According to Stebbins’ classification 268 patients could be classified as Tremor predominant (TD) 
73 as Postural Instability / Gait Difficulty (PIGD) and 37 as Indeterminate. 
Two-year follow up. 
At follow up 16.1% of patients (n=61) had no tremor, while 83.9% (n=317 of 378) had at least one 
component of tremor. 
Rest tremor was present in 67.9% of patients (n=257 of 378). Of these, 75.9% (n=195) had 
unilateral tremor while 23.7% (n=61) had bilateral tremor; only one patient (0.4%) had isolated lip / 
jaw tremor. Patients with bilateral tremor had significantly higher amplitude in the most affected 
limb (2.26 ± 0.73 vs 1.79 ± 0.68, P-value < 0.001), constancy (2.69 ± 1.04 vs 2.09 ± 1.05, P-value 
< 0.001) and index of rest tremor (6.44 ± 3.59 vs 4.13 ± 3.07, P-value < 0.001) compared to 
patients with unilateral tremor. The distributions of tremor scores across unilateral and bilateral 
tremor groups at follow up are reported in Table 43. 
Postural tremor was present in 49.5% of patients (n=187 of 378); 133 had unilateral postural 
tremor, while 54 had bilateral postural tremor; the mean ( SD) total postural tremor score in these 
patients was 1.65  0.92. 
Kinetic tremor affected 46.8% patients (n=177 of 378); 96 presented a unilateral kinetic tremor, 81 
a bilateral kinetic tremor; the mean ( SD) total kinetic tremor score in these patients was 1.76  
0.91. Results are summarised in Table 21. 
Among the 317 patients with tremor, 22.7% (n=72) presented with rest tremor alone, 7.3% (n=23) 
had kinetic tremor alone and 5.1% (n=16) had postural tremor alone. 16.4% (n=52) had rest and 
postural tremor; 11.0% (n=35) had rest and kinetic tremor and 6.6% (n=21) had postural and kinetic 
tremor. 30.9% of patients (n=98) presented all three types of tremor (Figure 2). 
Compared to patients with postural and/or kinetic tremors, patients presenting with rest tremor only 
showed significantly lower rigidity (3.78  2.663 vs 5.97  3.135, P-value < 0.001) and 
bradykinesia (7.88  4.487 vs 12.0  5.259, P-value < 0.001) (Supplementary Table 2). 
Phenotypically, 23 patients presented an isolated rest tremor, 122 patients had no rest tremor and 
233 had a mixed phenotype.  
Rest tremor scores in patients with isolated rest tremor were not significantly different compared to 
rest tremor scores in patients with a mixed phenotype (Supplementary Table 3).  
According to Stebbins’ classification 237 patients were Tremor predominant (TD), 105 Postural 
Instability / Gait Difficulty (PIGD) and 36 Indeterminate. 
 
Clinical Correlations  
The baseline correlations between rest tremor component scores and regional raphe 123I-FP-CIT 
binding in the PPMI cohort have been previously reported by our group and were not repeated in 
this paper. Briefly, we observed that in patients with isolated rest tremor a significant inverse 
association was present between raphe transporter binding and constancy of rest tremor (β = 
−0.380, P-value < 0.05) and the index of rest tremor (β = −0.322, P-value < 0.05). Moreover, 
significant inverse correlations between raphe transporter binding and rest tremor scores were 
observed in the entire cohort of 345 patients (Qamhawi et al., 2015). In our previous cross sectional 
baseline study on the PPMI cohort we did not find any correlations between severity of kinetic and 
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postural tremor components and serotonergic and dopaminergic neuronal dysfunction 
(Supplementary Table 4). 
At the two-year follow up, we studied the 173 patients who had both clinical and neuroimaging data 
available and were not taking serotonergic drugs. Only 14 of these patients presented with isolated 
rest tremor; in these patients, a significant inverse correlation was found between raphe transporter 
binding and rest tremor amplitude scores (Spearman’s  = −0.640, P-value < 0.05).  We did not 
find any significant correlation between raphe serotonin transporter availability and rest tremor 
constancy (Spearman’s  = −0.149, P-value = 0.612) or the index of rest tremor severity 
(Spearman’s  = −0.359, P-value = 0.208). 
Due to the paucity of patients with isolated rest tremor, we used Stebbins’ method (Stebbins et al., 
2013) in order to classify patients’ phenotype.  In 112 Tremor predominant (TD) patients, we again 
found significant inverse correlations between raphe serotonin transporter availability and rest 
tremor amplitude (Spearman’s  = −0.212, P-value < 0.05), rest tremor constancy (Spearman’s  = 
−0.195, P < 0.05) and the index of rest tremor severity (Spearman’s  = −0.192, P-value < 0.05).  
At follow up, however, across the entire Parkinson's disease cohort the correlations between raphe 
serotonin transporter and rest tremor scores were no longer significant (rest tremor amplitude: 
Spearman  = -0.077; P-value = 0.312; rest tremor constancy: Spearman  = -0.081; P-value = 
0.291; index of rest tremor: Spearman  = -0.088; P-value = 0.248). 
In order to better understand the combined contribution of serotonergic and dopaminergic 
dysfunction to the occurrence of rest tremor scores in the entire cohort, we interrogated the Raphe / 
Putamen 123I-FP-CIT binding ratio. At baseline, in the same cohort of 345 patients previously 
investigated, we found a significant inverse correlation between this ratio and rest tremor constancy 
(Spearman’s  = −0.141, P-value < 0.01) and the index of rest tremor severity (Spearman’s  = 
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−0.130, P-value < 0.05), while rest tremor amplitude showed an inverse but non-significant trend 
(Spearman’s  = −0.093, P-value = 0.083).  
In the cohort of 173 patients at the two-year follow up, the Raphe / Putamen 123I-FP-CIT binding 
ratio was significantly and inversely associated with rest tremor amplitude (Spearman’s  = 
−0.244, P-value < 0.01), rest tremor constancy (Spearman’s  = −0.264, P-value < 0.001) and the 
index of rest tremor severity (Spearman’s  = −0.252, P-value < 0.001); these results show that low 
ratios, expressing low raphe serotonin transporter availability coupled with relatively less severe 
putaminal dopamine terminals degeneration, are associated with higher tremor scores, while higher 
ratios, suggestive of more profound putaminal involvement and relatively higher serotonin 
transporter availability, are associated with lower tremor scores.  
The correlations between Raphe / Putamen ratio and tremor scores at baseline and follow up are 
summarised in table 54. 
 
Tremor response to dopaminergic therapy 
In the 38 patients with rest tremor amplitude > 0 who had both ON and OFF medication 
assessments at follow-up and were treated with either levodopa or a dopamine agonist alone, we 
found a significant direct association between the Raphe / Putamen 123I-FP-CIT binding ratio and 
the percentage improvement in rest tremor amplitude ( = 0.457, P-value < 0.01). Higher ratios, 
suggestive of more severe putaminal degeneration compared to raphe involvement, correlate with 
bigger improvements of tremor following acute dopamine replacement therapy, while lower ratios, 
suggestive of relatively greater raphe involvement associated with less severe putaminal 
degeneration, correlate with smaller therapeutic responses (Figure 3).  
 
Discussion 
To our knowledge this is the first study to comprehensively evaluate the clinical progression of 
tremor components together with neuroimaging correlates in a large cohort of well-characterised 
patients with early stage Parkinson's disease. One additional strength of the PPMI dataset is that the 
new MDS-UPDRS was used to separately score the amplitude and constancy of rest tremor, and 
postural and kinetic tremors as independent features. 
At baseline, tremor was present in the majority of patients (87.6%); most of them (79.3%) presented 
with rest tremor, either alone or associated with another component of tremor. Interestingly, more 
than 20% (20.7%) of early Parkinson's disease patients showing tremor did not have a classical rest 
tremor but presented with postural and/or kinetic tremor alone. Among the patients presenting with 
rest tremor, the majority (68.4%) had tremor in the upper limbs and only a small proportion (6.1%) 
had lower limb tremor. 
At the two-year follow up, tremor affected 84.1% of the cohort; again, the majority of these patients 
(67.9%) had rest tremor, alone or associated with another component of tremor, while 18.6% had 
postural and/or kinetic tremor alone. 
Postural and kinetic tremor were present in approximately half of the patients at both baseline and 
follow up. Interestingly, patients presenting with postural and/or kinetic tremors showed worse 
more severe rigidity and bradykinesia compared to patients with rest tremor only, both at baseline 
and follow up. This finding is likely to be related to the fact that patients with an isolated rest 
tremor component have a less severe putaminal dopaminergic loss of function, which is in turn 
associated with lower bradykinesia and rigidity compared to patients who do not exhibit rest tremor. 
We were unable to find previous studies that longitudinally assessed the prevalence of postural and 
kinetic tremors in a large cohort of idiopathic Parkinson's disease patients. 
The proportion of patients presenting with any component of tremor in this cohort at the early 
stages of the disease is slightly a little higher than previously reported in other studies: Hughes et 
al., reported a prevalence of tremor of 69% at disease onset and 75% during the course of the 
disease (Hughes et al., 1993); Rajput et al., reported that in 30 patients with pathologically 
confirmed cases of idiopathic Parkinson's disease tremor had been present in all patients at some 
point of the disease (Rajput et al., 1991). The higher proportion of patients with tremor in our 
cohort may reflect the fact that the MDS-UPDRS emphasises and rates the three different 
components of tremor separately. However, as study participants in the PPMI study were asked not 
to take anti-parkinsonian medication for at least six months, it is likely that tremor predominant 
subjects, who generally have less severe disability, were more ready to enter our study. 
A small reduction in the prevalence of all three components of tremor was observed from baseline 
to the two-year follow up. This reduction could simply reflect daily tremor variability or a residual 
effect of medications in the practically defined OFF state (see limitations); however, a reduction of 
the prevalence of tremor during the disease has been reported (Hughes et al., 1993; Toth et al., 
2004), possibly due to worsening in rigidity. A longer follow up might help confirm the same trend 
in this cohort.  
Interestingly, while the overall prevalence of tremor at follow up was slightly reduced, the 
proportion of patients with bilateral rest tremor more than doubled (9.8% vs 23.7%) over the two 
years, suggesting a rapid progression of rest tremor in these patients.  Also, at both baseline and 
follow up, patients with bilateral rest tremor presented higher rest tremor scores compared to 
patients with unilateral tremor. The proportion of patients with bilateral postural or kinetic tremors 
also showed a milder increasing trend.  
Phenotypically, we observed a reduction of patients presenting with “isolated rest tremor” (tremor 
with absent or very mild bradykinesia and rigidity) from baseline to the two-year follow up. 
Initially, tremulous patients showed significantly higher tremor scores compared to patients with a 
mixed phenotype; however, at the two year follow up, mean tremor scores were similar. This was 
due to the stability of rest tremor scores in tremulous patients and to increased scores in patients 
with a mixed phenotype. Again, it will be interesting to evaluate the trend of tremor scores at later 
follow-ups, even though a further reduction in the number of patients with isolated tremor might be 
expected, caused by increasing scores in rigidity and bradykinesia. 
 A previous study from our group on the PPMI cohort baseline data highlighted a significant inverse 
correlation between raphe transporter availability and tremor scores in a cohort of 345 Parkinson's 
disease patients, and in a subgroup of patients with a tremulous phenotype (Qamhawi et al., 2015).  
In the present study we analysed the two-year follow-up data of these patients: we found an 
analogous association in a group of 14 patients with a tremulous phenotype, and in 112 Tremor 
predominant patients. However, across the entire cohort such a correlation was no longer present: 
this could be due to the fact that as disease progresses a more severe dopaminergic deficit or other 
factors such as the degeneration of other neurotransmitter systems, influences the manifestation of 
tremor.  
In order to understand the combined contribution of the serotonergic and dopaminergic systems to 
the generation of tremor, raphe serotonin transporter binding values were normalised to putamen 
dopamine transporter binding values for each patient. This 123I-FP-CIT binding ratio (“Raphe / 
Putamen”) represents raphe serotonin transporter availability adjusted for nigro-putaminal 
degeneration in the single patient. We found that this Raphe / Putamen 123I-FP-CIT binding ratio 
was significantly associated with measures of tremor severity both at baseline and follow up. In 
particular, lower Raphe / Putamen 123I-FP-CIT binding ratios were associated with higher tremor 
scores, while higher ratios were associated with lower tremor scores. Therefore, higher tremor 
scores seem to be simultaneously associated with low raphe serotonin transporter availability 
coupled with a less severe dopaminergic dysfunction; conversely, lower tremor scores are 
associated with a relatively higher serotonin than dopamine transporter availability, due to more 
severe dopaminergic involvement.   
Post-mortem studies have highlighted that tremulous patients have a milder degeneration of 
substantia nigra pars compacta compared to rigid-akinetic patients (Paulus & Jellinger 1991; 
Selikhova et al., 2009). Several in vivo imaging studies have confirmed this finding (Spiegel et al., 
2007; Rossi et al., 2010; Helmich et al., 2011) and have reported the absence of a correlation 
between putamen dopamine transporter availability and tremor scores (Benamer et al., 2000; Pirker 
2003; Rossi et al., 2010).  In line with these studies, tremulous patients in the PPMI cohort had 
higher putamen dopamine transporter availability and lower raphe serotonin transporter availability 
compared to non-tremulous patients at baseline (Qamhawi et al., 2015). These studies demonstrate 
that tremulous patients have a less profound involvement of dopaminergic neurons in the substantia 
nigra compared to non-tremulous ones, and while nigro-striatal degeneration is necessary, it is not a 
sufficient factor in the generation of rest tremor (Deuschl et al., 2000). 
These and our findings, however, do not imply the cause of tremor, rather they illustrate that the 
dysfunction and/or degeneration of different neurochemical systems  have an important modulating 
role on the circuits responsible for facilitating tremor, as suggested by Dovzhenok and Rubchinsky 
(Dovzhenok and Rubchinsky, 2012). 
 
One of the most striking characteristics of Parkinsonian tremor is its variable response to 
dopaminergic therapy, as opposed to rigidity and bradykinesia (Fishman, 2008). We explored the 
response of tremor scores in 38 patients treated with levodopa or a dopamine agonist alone. We 
found a significant direct correlation between the Raphe / Putamen 123I-FP-CIT binding ratio and 
the percentage improvement of rest tremor amplitude scores (Figure 3). This means that patients 
with higher ratios, indicative of a relatively greater involvement of nigro-striatal dopaminergic 
system compared to the raphe serotonergic system, tend to respond better to dopaminergic therapy; 
in contrast, patients with lower ratios, representative of a greater dysfunction of the raphe coupled 
with a less severe involvement of dopaminergic terminals, tend to respond less to dopaminergic 
therapy. Therefore, from our analysis, it emerges that patients presenting tremor associated with a 
relatively large putaminal dopaminergic degeneration and less severe involvement of the raphe 
nuclei, respond better to dopaminergic treatment; this could be due to the fact that dopamine 
deficiency is, in these patients, the primary neurochemical cause of tremor. On the other hand, 
patients with a relatively bigger involvement of the raphe compared to the putamen, respond less; 
this, instead, could be due the fact that tremor in this subgroup of patients is driven not only by 
dopamine deficiency, but also by serotonergic dysfunction, and possibly by other neurotransmitter 
systems. Overall, these findings suggest that the concomitant neuroimaging evaluation of putamen 
dopaminergic terminals and raphe serotonergic nuclei could be important in the clinical setting in 
order to detect factors that might influence the response of tremor to dopaminergic medication. This 
might be particularly important in the subgroup of tremulous patients, in which tremor is the most 
disabling symptom. We can also hypothesize that patients presenting with a raphe-predominant 
degeneration might benefit from different treatments with respect to those with a putamen-
predominant degeneration. Further investigation in a more controlled setting is needed to better 
evaluate this relationship.  
 
We acknowledge that our study design presents has a number of limitations that need to be 
discussed. 
PPMI defines the OFF state as more than 6 hours from the last antiparkinsonian medication dose. It 
is possible that some of the longer acting dopamine agonist medications, and even levodopa, might 
still be affecting to a small extent the clinical ratings in this practically defined OFF state have 
affected, reasonably through a small effect, the OFF-state (Simuni et al., 2016). It is, therefore, 
possible that the decrease in the percentage of patients presenting with tremor at follow up was an 
in part a residual effect of medication; studies that allow for a longer medication wash-out time are 
needed to elucidate this pointhowever, as previously discussed, literature suggests otherwise and a 
longer follow up is needed to elucidate this point. As for the evaluation of the response of rest 
tremor to dopaminergic therapy, the use of the percentage improvement between the OFF and the 
ON states should have eliminated this possible confounding factor. 
70% of the patients recruited in the PPMI exhibited a Tremor Dominant phenotype at baseline. 
Such high percentage might have produced an overestimation of the proportion of patients 
presenting with tremor at both baseline and follow up. However, our results seem to fall in line with 
the data retrieved in the literature. 
At the time of the analysis only 173 patients had a valid 123I-FP-CIT SPECT scan for clinical 
correlation, as opposed to 345 patients at baseline. However, 173 patients are a reasonable number 
to trust the correlations we found. 
At the two-year follow up, only 38 patients had simultaneously a valid 123I-FP-CIT SPECT scan, 
rest tremor, and OFF and ON assessment during the same visit. Further investigation in a more 
controlled setting is needed (i.e. bigger number of patients, rest tremor instrumentally recorded, 
PET scans with a selective tracer for serotonergic neurons, etc.) in order to better characterize the 
relationship between imaging biomarkers and the variable response of tremor to different types of 
medications.  
We were unable to assess the test / retest variability of the Raphe / Putamen ratio, since patients 
underwent 123I-FP-CIT SPECT at screening, and at 12- and 24-months follow ups. However, we 
correlated individual patients’ baseline and follow up Raphe / Putamen ratios, and we found a 
strong positive correlation ( = 0.768, P-Value < 0.001) (Supplementary Figure 3). This finding 
suggests that the Raphe / Putamen ratio is a stable and reliable biomarker, at least at the initial 
stages of Parkinson’s disease. 
 
Conclusion 
Overall a high percentage of patients from the PPMI cohort presented with tremor at disease onset 
and it was still present after a follow up of two years. Rest tremor is the most represented 
component across the cohort, while postural and kinetic tremors affect approximately half of the 
patients.  
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Raphe serotonergic dysfunction appears to be a driver of the rest tremor clinically observed at 
baseline and at follow up, especially in patients with a predominantly tremulous phenotype. 
However, in order to better understand the pathophysiology of rest tremor, it is important to 
consider the concurrent role of putaminal dopamine deficiency. 
Last, we found that better responses of tremor amplitude to acute dopaminergic therapy were 
associated simultaneously with higher serotonin transporter availability and relatively more severe 
putaminal dopaminergic dysfunction (high Raphe / Putamen 123I-FP-CIT binding ratio). Therefore, 
tremor responsivity to dopaminergic therapy seems to be determined by an interaction between the 
serotonergic and dopaminergic systems, and non-dopaminergic treatments might be useful for those 




Data used in the preparation of this article were obtained from the Parkinson’s Progressive Markers 
Initiative (PPMI) database (www.ppmi-info.org/data); for up to date information on the study, visit 
www.ppmi-info.org.  
Parkinson’s Progression Markers Initiative – a public-private partnership – is funded by the Michael 
J. Fox Foundation for Parkinson’s Research and funding partners including AbbVie, Avid, Biogen, 
BioLegend Bristol-Myers Squibb, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, 
Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Sanofi Genzyme, Servier, Takeda, Teva, 
UCB, and Golub Capital. 
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Figure 1.  
A) Venn diagram of the distribution of the three types of tremor at baseline. Percentages are 
based on the 332 patients with tremor.  
B) Pie chart representing the subgroups of patients divided according to the types of tremor 
they present at baseline. Percentages are based on the whole cohort of 378 patients. 
 
  
Figure 2.  
A) Venn diagram of the distribution of the three types of tremor at the two-year follow up. 
Percentages are based on the 317 patients with tremor.  
B) Pie chart representing the subgroups of patients divided according to the types of tremor 
they present at the two-year follow up. Percentages are based on the whole cohort of 378 patients. 
  
Figure 3 Raphe / Putamen ratio association with the rest tremor amplitude percentage 
improvement 
Scatter plot showing Raphe / Putamen 123I-FP-CIT uptake ratio of 38 patients plotted against their 
respective percentage rest tremor amplitude improvement.  Line of best fit is shown. Patients taking 
levodopa only are represented by a green dot; patients taking a dopamine agonist only are 
represented by a blue square. The Raphe / Putamen ratio is associated with the percentage 
improvement of rest tremor amplitude ( = 0.457, P-value < 0.01).
 
Tables 
Table 1. Two-year follow up clinical and demographic characteristics of the 378 Parkinson’s 
disease patients included in our analysis. 
 
Feature 378 PD patients 
Age, years, mean  SD, (range) at baseline 63.1  12.2 (41-86) 
Gender (M/F) 248/130 
Disease duration, months  SD (range) at baseline 
30.79  6.72 (25-60) 
MDS- UPDRS III, mean 
 SD (range) 
Baseline 20.70  8.80 (4-51) 
24 months 25.9  11.4 (3-68) 
MDS- UPDRS total, 
mean  SD (range) 
Baseline 31.9  13.1 (7-70) 
24 months 42.2  17.4 (7-103) 
Hohen and Yahr, mean 
 SD, range (1-3) 
Baseline 1.55  0.51 (1-3) 
24 months 1.78  0.54 (1-4) 
Medication, n (%) 
 
Baseline No medication  
24 
months 
None 64 (16.9%) 
Levodopa 109 (28.8%) 
DA 69 (18.3%) 
Other PD medication 61 (16.1%) 
Combination of two or 




PD = Parkinon’s disease; MDS-UPDRS = Movement Disorders Society – Unified Parkinson’s 





Table 2. Prevalence of rest, postural and kinetic tremor in 378 patients at baseline and follow up. 
 
Characteristic Baseline Follow up 
Rest tremor, % 69.6 67.9 
Rest tremor – Unilateral vs 
Bilateral, % 
88.2 vs 10.3 75.9 vs 23.7 
Postural tremor, % 52.1 49.5 
Postural tremor – Unilateral vs 
Bilateral, % 
75.1 vs 24.9 71.1 vs 28.9 
Kinetic tremor, %  51.6 46.8 
Kinetic tremor – Unilateral vs 
Bilateral, % 
60.5 vs 39.5 54.2 vs 45.8 
Table 3 
Distributions of the highest rest tremor amplitude score (highest score in item 3.17) and rest tremor 
constancy (item 3.18 score) across groups with unilateral and bilateral tremor at baseline.  
For each of the two MDS-UPDRS items considered, the distribution of each score (from 1 to 4) is 




Group / Score  
 








43% 50% 7% 0% 
Bilateral tremor 
(27 patients) 






47% 25% 20% 8% 
Bilateral tremor 
(27 patients) 




Distributions of the highest rest tremor amplitude score (highest score in MDS-UPDRS item 3.17) 
and rest tremor constancy (MDS-UPDRS item 3.18 score) across groups with unilateral and 
bilateral tremor at follow up. 
For each of the two MDS-UPDRS items considered, the distribution of each score (from 1 to 4) is 




Group / Score  
 







36% 49% 15% 0% 
Bilateral tremor 
(61 patients) 






37% 29% 21% 13% 
Bilateral tremor 
(61 patients) 
16% 25 % 33% 26% 
 
  
 Table 5 
Association between the Raphe / Putamen ratio and rest tremor scores at baseline and two-year 
follow up (Spearman , asymptotic 2-tailed significance). 
 Raphe / Putamen ratio vs Spearman  P-value 
Baseline  
Rest tremor amplitude -0.093 0.083 
Rest tremor constancy -0.141 < 0.01 
Index of rest tremor -0.130 < 0.05 
Follow up 
Rest tremor amplitude -0.244 < 0.01 
Rest tremor constancy -0.264 < 0.001 
Index of rest tremor -0.252 < 0.001 
Baseline: number of patients = 345 
Follow up: number of patients = 173 
 



